Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NGM707 and Pembrolizumab in Advanced Solid Tumors
NCT07511972Phase 2Withdrawn
- Sponsor
- NGM Biopharmaceuticals
- Start
- Nov 2023
- Primary completion
- Dec 2024
- Modality
- Immune Checkpoint Inhibitors, Bispecific Antibodies
01
Overview
A Phase 2 trial of NGM707 in colorectal cancer (CRC), solid tumor, sponsored by NGM Biopharmaceuticals. Planned start Nov 2023; status: withdrawn.
02
Drugs
NGM707
03
Conditions
colorectal cancer (CRC)solid tumor
Beyond the preview
Go deeper on NCT07511972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07511972.